{"ticker": {"uuid": "5a328a8a-6845-40c9-ba0d-5de214bb0a96", "symbol": "ACAD", "name": "ACADIA Pharmaceuticals Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026", "summary": "Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced it will report its second quarter 2026 financial results on Tuesday, August 4, 2026, after the U.S. financial markets close. The company's management team will host a conference call and webcast on the same day at 4:30 p.m. Eas", "url": "https://www.biospace.com/press-releases/acadia-pharmaceuticals-to-announce-second-quarter-2026-financial-results-on-august-4-2026", "source_name": "BioSpace", "published_at": "2026-07-16T11:12:09", "published_display": "16 Jul 2026 11:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026", "summary": "Acadia Pharmaceuticals is set to release its second-quarter 2026 financial results on August 4, 2026. The announcement will be followed by a conference call and webcast to discuss the results and provide a business update.", "url": "https://www.moomoo.com/news/post/73033513/press-release-acadia-pharmaceuticals-to-announce-second-quarter-2026-financial?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-15T23:12:09", "published_display": "15 Jul 2026 23:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acadia Pharmaceuticals to announce Q2 2026 results on August 4", "summary": "Acadia Pharmaceuticals Inc. is set to release its Q2 2026 financial results on August 4, 2026, after the U.S. financial markets close. Following the release, the company will host a conference call and webcast at 4:30 p.m. ET to discuss its performance. This event will be accessi", "url": "https://scanx.trade/stock-market-news/companies/acadia-pharmaceuticals-to-announce-q2-2026-results-on-august-4/45697355", "source_name": "scanx.trade", "published_at": "2026-07-15T22:14:52", "published_display": "15 Jul 2026 22:14", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acadia to Host Q2 Results Call After Markets Close Aug. 4", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNQ0tmajF2UGVSUm1YQVJjeGFJWTZtQWQ0TDBkNDF4NFlBY3ZvaXpDTzFnd0pFbmtIM0dEY01JaTNnWG9uU0ZBWjU1NHh6cHU4eFZXRzlwZ0R3YjlkWXNva0Z5bTB5OTNwTHJVZWNWalVRRkxETVU0NUJwT3VVYmdmYnotSWpzMzlrS1BBV1N0ek5WRi11Mms1RlRjbmJ5R0Z4SU90R1VtYmZLbEtnUU5Nc1ZUNktqSGo0aUJN?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T20:08:11+00:00", "published_display": "15 Jul 2026 20:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxQSW9mM3I5d1lnaHgzVDlPNFgzSVg3MFNNVmk0N0hLcGh3dko0MF9kWUVzS1phTmdDU1NjUGFZamZZWTBmdnFfanllME9NWmhxd0JiMjJzM3JCQU9SVnY0cEx3T3JnT1pDUlh3Vy0xR1lDem9hZ2ZqdUFXd2UzU1JRbkczUEdHZ1hSRGdTN1JfSHgtLUxQVTBJRjNGbS15Z05pZVd0a25wZl9OX0VjNnp4WHVVOUxxeUVwbTJ1TmdMTzZvcEZVbTkzSDdEUFhvZTdtZC1fb3R2SFZ4ZzQ?oc=5", "source_name": "StockStory", "published_at": "2026-07-15T07:00:00+00:00", "published_display": "15 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "An Acadia Pharmaceuticals Insider Sold Nearly Half Their Shares in the Company. What Does That Mean for Investors?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9AFBVV95cUxPcVVlMDBxaE44dHB6OUk2WXR0SUpjbV9YNk82MkxWYjJxeGVoSlZrMF84VFJxZl9SZzNseGE2UE41ZTM0WmZ6Zm5hTERhdzhGOUNxYTdkcElSZTBZNDFXNGJVZ3ZISzExSXZNZTBXUVg0dDU2dzNTeFB5ZFc4NkcwcEVWZmJBR3F3aVNneGUwaUF3YVhIenN3U3VMd2tGTFhkMGhPQlhwZ1RZSlVWVU9IVmVyc21RekllNkJLNEs3OTNXVWN1N1BmYmsxUDBSamU2a3BOSU0xbUxBaFkyWUhZc3FDbUVmUF9hNkZ6TS1CakVrQllH?oc=5", "source_name": "The Motley Fool", "published_at": "2026-07-11T21:50:00+00:00", "published_display": "11 Jul 2026 21:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACADIA Pharmaceuticals (ACAD) Names A New Chief People Officer, Is It Still Below Fair Value?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOWTVpM2t2U1BMVEdUVjRNSGhoX1A3cUttZ192SlZIaVpJOWJqVjR1UkNRV1VCZDRORGlDLTJPaW1fNm9HaGh5V29RSDJHNmVYQ0xrcF9rZTFsN2t3RENJVzVCaHNfU1hjSktudThCMlIyZGZxMGg2akExdHlKV0tybmZWcmNPOUEyb3lmRkNYT2tzMTdxTDVIRjRHQV96MndDUFA1czlaNA?oc=5", "source_name": "Market source", "published_at": "2026-07-11T02:09:00+00:00", "published_display": "11 Jul 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Keeps Their Buy Rating on ACADIA Pharmaceuticals (ACAD)", "summary": "H.C. Wainwright analyst Ananda Ghosh reiterated a Buy rating for ACADIA Pharmaceuticals (ACAD) on July 7, setting a price target of $27.00. This follows other analyst actions, with RBC Capital also giving a Buy rating, while Morgan Stanley maintained a Hold rating. The company re", "url": "https://www.theglobeandmail.com/investing/markets/stocks/ACAD/pressreleases/3220936/hc-wainwright-keeps-their-buy-rating-on-acadia-pharmaceuticals-acad/", "source_name": "The Globe and Mail", "published_at": "2026-07-11T00:41:10", "published_display": "11 Jul 2026 00:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACADIA Pharmaceuticals (ACAD) Stock Looks Undervalued After A 21% Run", "summary": "ACADIA Pharmaceuticals (ACAD) stock has seen a 20.5% return over the past year but is still considered undervalued based on current checks. Despite positive news from the European Medicines Agency regarding Daybu, the stock's P/E ratio of 11.9x is significantly below the biotech ", "url": "https://www.sahmcapital.com/news/content/acadia-pharmaceuticals-acad-stock-looks-undervalued-after-a-21-run-2026-07-09", "source_name": "Sahm", "published_at": "2026-07-10T15:39:36", "published_display": "10 Jul 2026 15:39", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is ACADIA Pharmaceuticals (ACAD) Still Undervalued After The Daybue Win?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxPMzlXSENWLTU4cFJmQkZVbDhmQ0t2TmJnaGNPdUtJOGpLZUJZTVd4Ym9qRTh4Q3ZTNU1Jakg1STJjcHYzeWZnTlc1NGZEeWpHR2o0R2ZOS21ub1JYMEFQT1c1enZVOWJ5SVE4ZktLMmt0bEQteGNVOHJkb2hmMmt6clJiWGtQeFpXY1dseU01dUJIaGxocWo3bGV1Q2RzTmc0TGI2REdJUGdnRU1jd3dV?oc=5", "source_name": "Market source", "published_at": "2026-07-10T14:15:36+00:00", "published_display": "10 Jul 2026 14:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How CHMP\u2019s Positive Rett Syndrome Ruling on DAYBU Could Impact ACADIA Pharmaceuticals (ACAD) Investors", "summary": "ACADIA Pharmaceuticals received a positive opinion from the EMA's CHMP for DAYBU to treat Rett syndrome in Europe, potentially making it the first approved therapy for the condition in the EU. This development could expand treatment options for patients and reinforce Acadia's rev", "url": "https://finance.yahoo.com/healthcare/articles/chmp-positive-rett-syndrome-ruling-131241856.html", "source_name": "Market source", "published_at": "2026-07-10T13:39:36", "published_display": "10 Jul 2026 13:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is ACADIA Pharmaceuticals (ACAD) Undervalued On Rett Progress And Its Leadership Change?", "summary": "ACADIA Pharmaceuticals is gaining attention due to a recent leadership appointment and a positive European regulatory opinion for its Rett syndrome therapy, DAYBU. The company's stock has seen strong performance with a 20.9% return over 30 days and a 19.7% one-year return. Despit", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-acad/acadia-pharmaceuticals/news/is-acadia-pharmaceuticals-acad-undervalued-on-rett-progress", "source_name": "Simply Wall Street", "published_at": "2026-07-10T13:39:36", "published_display": "10 Jul 2026 13:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should EMA\u2019s Positive Rett Syndrome Opinion for DAYBU Reshape ACADIA Pharmaceuticals\u2019 (ACAD) Investment Narrative?", "summary": "ACADIA Pharmaceuticals recently received positive news from the European Medicines Agency (EMA) regarding DAYBU (trofinetide) for Rett syndrome, potentially expanding its market in Europe. While this development could strengthen DAYBU's position as a second revenue pillar next to", "url": "https://www.sahmcapital.com/news/content/should-emas-positive-rett-syndrome-opinion-for-daybu-reshape-acadia-pharmaceuticals-acad-investment-narrative-2026-07-07", "source_name": "Sahm", "published_at": "2026-07-08T23:39:36", "published_display": "08 Jul 2026 23:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of ACADIA Pharmaceuticals Inc. \u2013 NASDAQ:ACAD", "summary": "This page displays the enterprise value to EBITDA forward for ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD). The data is provided by ICE Data Services and FactSet, focusing on the financial metrics for the company within the pharmaceuticals sector.", "url": "https://www.tradingview.com/symbols/NASDAQ-ACAD/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T01:11:27", "published_display": "08 Jul 2026 01:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital Adjusts Price Target on ACADIA Pharmaceuticals to $36 From $29, Maintains Outperform Rating", "summary": "RBC Capital has increased its price target for ACADIA Pharmaceuticals (ACAD) to $36 from $29, while reiterating an Outperform rating on the stock. This adjustment reflects the firm's updated valuation of the company.", "url": "https://www.moomoo.com/news/post/72582431/rbc-capital-adjusts-price-target-on-acadia-pharmaceuticals-to-36?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-07T13:09:41", "published_display": "07 Jul 2026 13:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer", "summary": "Acadia Pharmaceuticals Inc. has announced the appointment of Carl Segerstrom as Chief People Officer, effective July 6, 2026. Segerstrom will oversee the company's global people and culture strategy, supporting its expansion as a leading neurological and rare disease company. He ", "url": "https://www.biospace.com/press-releases/acadia-pharmaceuticals-appoints-carl-segerstrom-as-chief-people-officer", "source_name": "BioSpace", "published_at": "2026-07-07T11:40:33", "published_display": "07 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acadia taps 25-year HR veteran for chief people officer role", "summary": "Acadia Pharmaceuticals Inc. has appointed Carl Segerstrom as its new Chief People Officer, effective July 6. Segerstrom, who brings over 25 years of global human resources experience from the biopharmaceutical industry, will lead the company's people and culture strategy to suppo", "url": "https://www.stocktitan.net/news/ACAD/acadia-pharmaceuticals-appoints-carl-segerstrom-as-chief-people-lllmyr75lgdp.html", "source_name": "Stock Titan", "published_at": "2026-07-06T12:40:03", "published_display": "06 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of ACADIA Pharmaceuticals Inc. \u2013 LSX:603035", "summary": "The article discusses the \"Price to book forward\" metric for ACADIA Pharmaceuticals Inc. (LSX:603035). It appears to be a financial data snippet from TradingView, indicating that the market for this stock was closed with no trades recorded. The content does not provide specific f", "url": "https://www.tradingview.com/symbols/LSX-603035/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T22:40:03", "published_display": "05 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACAD - Acadia Pharmaceuticals Inc Forecast, Target Price", "summary": "This article provides comprehensive financial data for Acadia Pharmaceuticals Inc. (ACAD), including key metrics like market capitalization, P/E ratio, EPS forecasts, and sales performance. It also details insider and institutional ownership, profitability ratios, and various sto", "url": "https://finviz.com/stock?t=ACAD&ta=1&p=d&ty=fc&r=m6", "source_name": "Finviz", "published_at": "2026-07-05T22:40:03", "published_display": "05 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of ACADIA Pharmaceuticals Inc. \u2013 NASDAQ:ACAD", "summary": "This article provides access to the \"Price to sales forward\" financial metric for ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) on TradingView. It indicates that the market was closed at the time of publication and offers no trades. The content primarily focuses on navigation to fin", "url": "https://www.tradingview.com/symbols/NASDAQ-ACAD/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T13:11:46", "published_display": "05 Jul 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACAD INVESTORS WHO LOST MONEY: HAGENS BERMAN, National Trial Attorneys, Alerts Acadia Pharmaceuticals (ACAD) Investors to Securities Class Action, Advises Investors with Losses to Contact Its Attorneys Now", "summary": "Hagens Berman, a national trial law firm, is alerting investors of Acadia Pharmaceuticals (NASDAQ: ACAD) to a securities class action lawsuit. The lawsuit alleges that Acadia misrepresented facts concerning its supplemental new drug application (\"sNDA\") for NUPLAZID\u00ae (pimavanseri", "url": "https://www.newsfilecorp.com/release/83505/ACAD-INVESTORS-WHO-LOST-MONEY-HAGENS-BERMAN-National-Trial-Attorneys-Alerts-Acadia-Pharmaceuticals-ACAD-Investors-to-Securities-Class-Action-Advises-Investors-with-Losses-to-Contact-Its-Attorneys-Now?lang=fr", "source_name": "TMX Newsfile", "published_at": "2026-07-01T21:09:07", "published_display": "01 Jul 2026 21:09", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACADIA Pharmaceuticals (ACAD) In Focus As Europe Backs Daybue And Undervalued View Holds", "summary": "ACADIA Pharmaceuticals (ACAD) shares are in focus after European regulators issued a positive opinion on Daybue for Rett syndrome, causing a recent rally. Despite a 16.34% one-month return, the stock is still down 4.15% year-to-date and is considered 12.3% undervalued with a fair", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-acad/acadia-pharmaceuticals/news/acadia-pharmaceuticals-acad-in-focus-as-europe-backs-daybue", "source_name": "Simply Wall Street", "published_at": "2026-06-30T20:10:23", "published_display": "30 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Acadia Pharmaceuticals stock rating on EU progress", "summary": "H.C. Wainwright reaffirmed its Buy rating and $37 price target for Acadia Pharmaceuticals (NASDAQ:ACAD) after the CHMP issued a positive opinion for DAYBU (trofinetide) in Europe. This decision reverses a previous refusal and recommends marketing authorization for neurobehavioral", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-acadia-pharmaceuticals-stock-rating-on-eu-progress-93CH-4767555", "source_name": "Investing.com", "published_at": "2026-06-30T12:09:47", "published_display": "30 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 ACADIA Pharmaceuticals Inc For: 29 June By Investing.com", "summary": "This article announces the filing of Form 4 for ACADIA Pharmaceuticals Inc. on June 29. It includes basic information about the company and its stock performance, along with a statement from Reuters. The primary content is a headline and brief stock data.", "url": "https://ca.investing.com/news/stock-market-news/form-4-acadia-pharmaceuticals-inc-for-29-june-93CH-4712731", "source_name": "Investing.com Canada", "published_at": "2026-06-29T22:09:47", "published_display": "29 Jun 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACADIA PHARMACEUTICALS (ACAD) officer sells 11,421 shares under 10b5-1 plan", "summary": "ACADIA PHARMACEUTICALS' Principal Accounting Officer, James Kihara, sold 11,421 shares of common stock at a weighted average price of $26.0846 per share. This open-market transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 9, 2025. Follow", "url": "https://www.stocktitan.net/sec-filings/ACAD/form-4-acadia-pharmaceuticals-inc-insider-trading-activity-e01ea9f69012.html", "source_name": "Stock Titan", "published_at": "2026-06-29T21:41:28", "published_display": "29 Jun 2026 21:41", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACADIA Pharmaceuticals Price Target Raised to $35.00/Share From $32.00 by Citigroup", "summary": "Citigroup has increased its price target for ACADIA Pharmaceuticals from $32.00 to $35.00 per share. This adjustment indicates a more optimistic outlook by the firm on the company's future stock performance.", "url": "https://www.moomoo.com/news/post/72197256/acadia-pharmaceuticals-price-target-raised-to-35-00-share-from?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-29T13:41:29", "published_display": "29 Jun 2026 13:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acadia Pharmaceuticals: Steady Commercial Progress, Remlifanserin Data In Focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQSHRVYTZYd0M0LWtaOUxJRDdkVk9iVGF2RDhSQ2V3SHowdHFrNUE2MnVLd3lqWVl4bDhjSFFBT19SelpmcndyRnVheFFHN1ZhRXFRaEpQQ2VMbGVhX0ZMUFlQVTY5cGtCUFVXR3Rab2FZSXZSUTBiYWxUUzN4Q3VnOFVmSHc2MWwxTXZUdmtyUUJtSUtMSFdqTkRnVU9hM2ZDejdYSWJHQlpLeHRQQWozYnBKZUhORnM3aUE?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Strength Seen in Acadia (ACAD): Can Its 6.8% Jump Turn into More Strength?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQMUdvaE8yS3ZMb19vQlFhV2U0c0F6TGt4UnJpMmhfUVFXQ0UwQUZUUXFKSFRBWGlGdGhzbVNBTVlYMHZHVDJHR0JOSzFWendCN3lKd0RZTE5NWEpJZWtiN2lTMEFwa2paQ29KTHB1TjlXYTNjWk9UeFFkU0ItakRReFFuSUl2WWFHbnBMdHQyeGRleVJzcmxz?oc=5", "source_name": "Market source", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acadia Pharma Stock Jumps After European Panel Reverses Course On Rett Syndrome Therapy", "summary": "Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) shares are trading higher after the European Medicines Agency (CHMP) recommended granting marketing authorization for its drug DAYBU (trofinetide) to treat neurobehavioral symptoms of Rett syndrome in the EU. This follows an earlier nega", "url": "https://www.sahmcapital.com/news/content/acadia-pharma-stock-jumps-after-european-panel-reverses-course-on-rett-syndrome-therapy-2026-06-26", "source_name": "Sahm", "published_at": "2026-06-28T20:39:37", "published_display": "28 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why ACADIA Pharmaceuticals (ACAD) Is Up 17.1% After EMA Backs DAYBU For Rett Syndrome", "summary": "ACADIA Pharmaceuticals saw its stock rise by 17.1% after the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for DAYBUE (trofinetide) to treat Rett syndrome in the EU. This potential approval would make DAYBUE the first approved therapy for ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-acad/acadia-pharmaceuticals/news/why-acadia-pharmaceuticals-acad-is-up-171-after-ema-backs-da", "source_name": "Simply Wall Street", "published_at": "2026-06-28T07:39:48", "published_display": "28 Jun 2026 07:39", "sentiment": "positive", "sentiment_pct": 82, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACADIA Pharmaceuticals Up Nearly 11%, On Track for Largest Percent Increase Since May 2025 -- Data Talk", "summary": "ACADIA Pharmaceuticals (ACAD) shares increased by nearly 11% today, putting the company on track for its largest single-day percentage gain since May 2025. This significant rise highlights strong investor interest, potentially driven by recent developments or market optimism surr", "url": "https://www.moomoo.com/news/post/72119989/acadia-pharmaceuticals-up-nearly-11-on-track-for-largest-percent?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-27T07:09:58", "published_display": "27 Jun 2026 07:09", "sentiment": "positive", "sentiment_pct": 78, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] ACADIA PHARMACEUTICALS INC SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOdmlWd3FBQ1FrQTJYTGtqaF9QRkdXazhuNk5TbzNCNlZ3SDRaNENDOElvSXRGMHZQMFd6VDViX0Y5THJZazhxVHNYa3UzandGNDQ4b0ozR21QdkdpSVZ4eXJsMy1ZLW1YS2V2U3k1SExvb05ZR01EcEJmN2dveXkwcHlMTmkyQnNub3VKYkZnSnhoUmRiVUxmTHU2WkxHQmZ0Y3lTRnBn?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Acadia Pharmaceuticals Stock Is Soaring Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNTWxCUkpKUDhWSmV6RlFNakZHUjAwUTBLYk9EOFZyaUNSYzhsaE9wck1oTDRBb3hmWExaaHNoSGpSSTlXZ0J3QXJZMFNUa2l1TnJiS3VXd2lsQmVLR3BjSDl4UlAtMzFWZldwYWJlSlB1S2RUdm45NU5oVGVGMkQtVm4wbGd2UEZPdlFTaHdZQklBaFppQkh4STFxZ3RvTm4yQ0VFbnVCNXc?oc=5", "source_name": "Market source", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EU regulator backs Acadia's DAYBU for Rett syndrome", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPNFBnT2VUcDl2bUZGVTlOaUd3NlhRem9sRmh2aUFEWDYtRzdFamlTTVEtU2gxNTA5OUpXWDZMMWlTTFNrcW81d0xJWmVaUHowUzg0MllMRVV6aVFKQ1h1VS1Ma2J0N3ZuRXpWU1JqZWQzM2h2Z0dBQnhMRFZfYndkdktqUmRuYWJKeDFZMDVVVVRpWmJldGwxZTJUaEdBanBTR29fYU82cnNtWWxyZ21zOE9BSkNPMnhpSWJKdlN0Yw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACADIA Pharmaceuticals Inc. Actuals & Estimates (NASDAQ:ACAD)", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNZkhhX0xxalNLNF9waXRtNHdFaEZaV2RodUtWZXV2SUREV1FTUzM0ek41dzNnTGNsUWlZQWRzQ1dvWndlTUVkejg1cmQzd2JRZ2drTXFiTXpLdVMtWGx4eDJfd1lvZTBjakJQZVVpNzB4STlDMXVWOENiMHg1bHJOcUM1Vzk1QQ?oc=5", "source_name": "TradingView", "published_at": "2026-06-25T21:27:33+00:00", "published_display": "25 Jun 2026 21:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACADIA Pharmaceuticals: The Song Remains The Same (NASDAQ:ACAD)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNYUVvSnJZRERCZkFRVjlqYkFVX2JBNGVQSHNhbXQ4eUpTUUQtS2YwMUhmQVYzSXp3c1JBcnBjWERVLXpoUmgzT3MtS1dYMW5COXhxUFBBbGpMUmF5YnVtWTdSQjA5ai02aXNTTERiUW1NNVpITDVxaWI2QlJHWkpoRXZTLXRyc2VC?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACADIA Pharmaceuticals stock (US0042251084): earnings momentum and pipeline focus in neuroscience", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPUHpvTkZzM0pRZGdTWTRsVGNoRnZHOFd5TDcyN053bHZWeUFWdUNVRm92NlUxamZ3Ti1rVXg2YVdSMTlCbUIyS0VzV0tCM044Zjk3NmR2M0JjbXloaWl4cVpoVTl1YUFkVVhoQ3lIdlFsUGoyQU9RbTFwU3VELXpHOF9McHN4dlBVZHZGWThUYzdHbVYxZEtBV1Rkd0w3dS1NUkQzd2tEeFkzYUtjLTNxUE82UnU4Z1A5czhGZnpmSQ?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At ACADIA Pharmaceuticals (ACAD) Valuation After Recent Share Price Weakness", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOeWNzOWNoM0QteERGa2VjeHFnZ0ZLVWgyVGUyeDJRZjNqX0UtU2ZoRHRUektHMjY4cVhQYU01S3FWRnZ3Y3hkbURtNTR3ejZrcnlPRjZEUnAxY1J1SnQ0U2hLODdDUzRRVlZwZGNhM0NsTzY4X29mRlFsWlp3YWV1cGl4S3Zic1hQcGV4ZmhDQnJfWnBKSWl6VEtvYmxLejBxc00tT0JlbkVVNTQ?oc=5", "source_name": "Market source", "published_at": "2026-06-07T07:00:00+00:00", "published_display": "07 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Shareholders In ACADIA Pharmaceuticals (NASDAQ:ACAD) Should Look Beyond Earnings For The Full Story", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNMG1naUZNQXpCa2RmYVhEWGlNTFNsYXlMS2N3LUk3cnBXY0dPTElXYWV5ZTY2STBvd1dxMFBXTTlldGd6MVRuYS03Z0wzdTNwcHI0cTRkeGwxcmxFYjBOXzdfd1RqQ1lTbGRRbkVTM05lNWJQbFY3THpzbFlpb1JYNHRJcHhUdVd1Ql9yREdSd2hXQ2k3ZDc5NjNZRDZMbkJVc2RuM2VpSkRNcjFsazd1ZzBR?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is ACADIA Pharmaceuticals (ACAD) Offering Value After A 45% One Year Share Price Gain?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7AFBVV95cUxNS3B4Zl9Gc0ZxOTFmamtvelkzaUxYVkNIV0FZTDlVUThlbnpYZDF5MWVzTkl6VFJBY0thVlNSVzBaQjRSdmhSdEtMaGoyOVpmVmg0M2ZBUEwtTzA1VmxEenR6b1NmcDJic0NpbFJWQUtYa3BSVEpHTGs5eEVOVzZLMVFwbXp5QTFIdUo0VEF0QzVuUXROY3h1ekxGcU1SdWpQamNsanZNc0NqN1ExLTVCWVNVSHl3QWFBcFdfTVFjb3VxM3FIcFpveWwyVERLVTB3ZDlOVmZNQXg0ZUIwZzI4Mm1XRllKT0xNY04xUtIB8gFBVV95cUxNOEMwZ3FIT1ZjUV8zMmhSTGxXV1ZQV2QwWDFUX1RIYXVSWEpaNDFVeEp6UHJCemU3OWd3NHRhSW1yVld4SFVFckhpQ1lQV3U4SlJiQS15cVdqS3ViNWtSRTFRQlhnWkhmajJGUGplX1hOSEc5Mkl4cG9vdG8zRUhCdU5PMXMxMzZMREx1bXh3eXo5QmVmb0NLVlJkcGdjZkJzb3lCczYydWJ0SHI3bXpGc0tSaDZYN1B6R1hvRUtjdjNVSElMejg0Y2hCQy1DQUpXcmF6bVh1LWxmSGlKTTJ3a1FDcGlCZjMyQ0YyVHY1YWp3dw?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acadia R&D Chief Plans Retirement As Company Stresses Pipeline Continuity", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-03T07:00:00+00:00", "published_display": "03 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "ACADIA PHARMACEUTICALS INC ($ACAD) CEO 2025 Pay Revealed", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNMUh2aTY1QjZOZzJ4UE1mSGMxVjhEM3hBd2ZFMGRyYldGRXRpbnF4UkpyN3ptVktkVG9hNHdWbkVqdGVvMUNxNnhIZmF0VGgxVzNJMWFQNDE2S3djbUhqZ1phcW93bEZDRFdWZGdLaUZMNEpRa2RDeGg1NEgwNjF4eTJXM3c0cWRRZDNKNzQ0YmJQbVJiemxZOTNCQQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "CNBC Cures: Acadia Pharmaceuticals CEO on scaling rare and neuro-focused drugs", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQcDBtTjR6dGE4LWNaRFZJaFh0MWxqV0FUNjZEWm5CYjZrUV9jN01EUzZYWVhGSUR5UUJldkFWTTZiTE8xdUNqd0habHh1TFlwWndhdlJDTTFZVG9FTmZqSXBFU1NBZjJfVWZaVXpvSDJ5QmhJOWhGV3VaaldZNktCZ2lGbGF4cG4zX3NRd0hUM0pRY183eWtlUmJvYmJpOGVJaFV5MjkwRm9yWWJ2Q1N6OVFVYnFEaXdRNVFJWg?oc=5", "source_name": "CNBC", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Revisit ACADIA Pharmaceuticals (ACAD) After Recent Share Price Weakness?", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxQemhIOTQxVGdualF2NHdkNk5TRGxwQ1p6a0l0V2NEaDFJczZmRzAxZnRTRGx2NDhoR1JTNmc5X1F2eHNDclAwV2ZnT2NfZXBUWUZtSkpQOUtBal9acW5BUVRsZHFhZXk1WG56anlkODJSRUQ2cmZNbVcya0lYdlQ0UFJtekEyendobzV6TzI1WQ?oc=5", "source_name": "Market source", "published_at": "2026-03-04T08:00:00+00:00", "published_display": "04 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will ACADIA Pharmaceuticals' (ACAD) 2025 Earnings Beat and 2026 Guidance Shift Its Growth Narrative?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxOMlNJdm53WXJkaE1PVXJGYmhBbnBCOU13cE52djB4VDZDazhzTFFrMndIdVhsZEliVjMyREh5dHhWN21NRVNKdmtRN3lsT0Flb3J0NWhHVmhFeEJvR1hPeHM5bWtzSHZySE9vMV8wQ3pYZzdlNVNqME5yVnFzcmhuRXdINEdKX1ZaYVVjdXhtTmw?oc=5", "source_name": "Market source", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACADIA Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-09T08:00:00+00:00", "published_display": "09 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acadia Pharmaceuticals (ACAD) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1YMlYxeXZrMkFqbmpBb3VrWlJZb1ZmYjdDYXBfZmd3blFwMGpxYnhJRnBWUFdfbkRpRVkydV9lWjdWbW5NVllMNFdKVjNKSmVVeXBV?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T01:14:47+00:00", "published_display": "25 Apr 2025 01:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026", "summary": "Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced it will report its second quarter 2026 financial results on Tuesday, August 4, 2026, after the U.S. financial markets close. The company's management team will host a conference call and webcast on the same day at 4:30 p.m. Eas", "url": "https://www.biospace.com/press-releases/acadia-pharmaceuticals-to-announce-second-quarter-2026-financial-results-on-august-4-2026", "source_name": "BioSpace", "published_at": "2026-07-16T11:12:09", "published_display": "16 Jul 2026 11:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026", "summary": "Acadia Pharmaceuticals is set to release its second-quarter 2026 financial results on August 4, 2026. The announcement will be followed by a conference call and webcast to discuss the results and provide a business update.", "url": "https://www.moomoo.com/news/post/73033513/press-release-acadia-pharmaceuticals-to-announce-second-quarter-2026-financial?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-15T23:12:09", "published_display": "15 Jul 2026 23:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acadia Pharmaceuticals to announce Q2 2026 results on August 4", "summary": "Acadia Pharmaceuticals Inc. is set to release its Q2 2026 financial results on August 4, 2026, after the U.S. financial markets close. Following the release, the company will host a conference call and webcast at 4:30 p.m. ET to discuss its performance. This event will be accessi", "url": "https://scanx.trade/stock-market-news/companies/acadia-pharmaceuticals-to-announce-q2-2026-results-on-august-4/45697355", "source_name": "scanx.trade", "published_at": "2026-07-15T22:14:52", "published_display": "15 Jul 2026 22:14", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acadia to Host Q2 Results Call After Markets Close Aug. 4", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNQ0tmajF2UGVSUm1YQVJjeGFJWTZtQWQ0TDBkNDF4NFlBY3ZvaXpDTzFnd0pFbmtIM0dEY01JaTNnWG9uU0ZBWjU1NHh6cHU4eFZXRzlwZ0R3YjlkWXNva0Z5bTB5OTNwTHJVZWNWalVRRkxETVU0NUJwT3VVYmdmYnotSWpzMzlrS1BBV1N0ek5WRi11Mms1RlRjbmJ5R0Z4SU90R1VtYmZLbEtnUU5Nc1ZUNktqSGo0aUJN?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T20:08:11+00:00", "published_display": "15 Jul 2026 20:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "An Acadia Pharmaceuticals Insider Sold Nearly Half Their Shares in the Company. What Does That Mean for Investors?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9AFBVV95cUxPcVVlMDBxaE44dHB6OUk2WXR0SUpjbV9YNk82MkxWYjJxeGVoSlZrMF84VFJxZl9SZzNseGE2UE41ZTM0WmZ6Zm5hTERhdzhGOUNxYTdkcElSZTBZNDFXNGJVZ3ZISzExSXZNZTBXUVg0dDU2dzNTeFB5ZFc4NkcwcEVWZmJBR3F3aVNneGUwaUF3YVhIenN3U3VMd2tGTFhkMGhPQlhwZ1RZSlVWVU9IVmVyc21RekllNkJLNEs3OTNXVWN1N1BmYmsxUDBSamU2a3BOSU0xbUxBaFkyWUhZc3FDbUVmUF9hNkZ6TS1CakVrQllH?oc=5", "source_name": "The Motley Fool", "published_at": "2026-07-11T21:50:00+00:00", "published_display": "11 Jul 2026 21:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACADIA Pharmaceuticals (ACAD) Names A New Chief People Officer, Is It Still Below Fair Value?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOWTVpM2t2U1BMVEdUVjRNSGhoX1A3cUttZ192SlZIaVpJOWJqVjR1UkNRV1VCZDRORGlDLTJPaW1fNm9HaGh5V29RSDJHNmVYQ0xrcF9rZTFsN2t3RENJVzVCaHNfU1hjSktudThCMlIyZGZxMGg2akExdHlKV0tybmZWcmNPOUEyb3lmRkNYT2tzMTdxTDVIRjRHQV96MndDUFA1czlaNA?oc=5", "source_name": "Market source", "published_at": "2026-07-11T02:09:00+00:00", "published_display": "11 Jul 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Keeps Their Buy Rating on ACADIA Pharmaceuticals (ACAD)", "summary": "H.C. Wainwright analyst Ananda Ghosh reiterated a Buy rating for ACADIA Pharmaceuticals (ACAD) on July 7, setting a price target of $27.00. This follows other analyst actions, with RBC Capital also giving a Buy rating, while Morgan Stanley maintained a Hold rating. The company re", "url": "https://www.theglobeandmail.com/investing/markets/stocks/ACAD/pressreleases/3220936/hc-wainwright-keeps-their-buy-rating-on-acadia-pharmaceuticals-acad/", "source_name": "The Globe and Mail", "published_at": "2026-07-11T00:41:10", "published_display": "11 Jul 2026 00:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACADIA Pharmaceuticals (ACAD) Stock Looks Undervalued After A 21% Run", "summary": "ACADIA Pharmaceuticals (ACAD) stock has seen a 20.5% return over the past year but is still considered undervalued based on current checks. Despite positive news from the European Medicines Agency regarding Daybu, the stock's P/E ratio of 11.9x is significantly below the biotech ", "url": "https://www.sahmcapital.com/news/content/acadia-pharmaceuticals-acad-stock-looks-undervalued-after-a-21-run-2026-07-09", "source_name": "Sahm", "published_at": "2026-07-10T15:39:36", "published_display": "10 Jul 2026 15:39", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is ACADIA Pharmaceuticals (ACAD) Still Undervalued After The Daybue Win?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxPMzlXSENWLTU4cFJmQkZVbDhmQ0t2TmJnaGNPdUtJOGpLZUJZTVd4Ym9qRTh4Q3ZTNU1Jakg1STJjcHYzeWZnTlc1NGZEeWpHR2o0R2ZOS21ub1JYMEFQT1c1enZVOWJ5SVE4ZktLMmt0bEQteGNVOHJkb2hmMmt6clJiWGtQeFpXY1dseU01dUJIaGxocWo3bGV1Q2RzTmc0TGI2REdJUGdnRU1jd3dV?oc=5", "source_name": "Market source", "published_at": "2026-07-10T14:15:36+00:00", "published_display": "10 Jul 2026 14:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How CHMP\u2019s Positive Rett Syndrome Ruling on DAYBU Could Impact ACADIA Pharmaceuticals (ACAD) Investors", "summary": "ACADIA Pharmaceuticals received a positive opinion from the EMA's CHMP for DAYBU to treat Rett syndrome in Europe, potentially making it the first approved therapy for the condition in the EU. This development could expand treatment options for patients and reinforce Acadia's rev", "url": "https://finance.yahoo.com/healthcare/articles/chmp-positive-rett-syndrome-ruling-131241856.html", "source_name": "Market source", "published_at": "2026-07-10T13:39:36", "published_display": "10 Jul 2026 13:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is ACADIA Pharmaceuticals (ACAD) Undervalued On Rett Progress And Its Leadership Change?", "summary": "ACADIA Pharmaceuticals is gaining attention due to a recent leadership appointment and a positive European regulatory opinion for its Rett syndrome therapy, DAYBU. The company's stock has seen strong performance with a 20.9% return over 30 days and a 19.7% one-year return. Despit", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-acad/acadia-pharmaceuticals/news/is-acadia-pharmaceuticals-acad-undervalued-on-rett-progress", "source_name": "Simply Wall Street", "published_at": "2026-07-10T13:39:36", "published_display": "10 Jul 2026 13:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should EMA\u2019s Positive Rett Syndrome Opinion for DAYBU Reshape ACADIA Pharmaceuticals\u2019 (ACAD) Investment Narrative?", "summary": "ACADIA Pharmaceuticals recently received positive news from the European Medicines Agency (EMA) regarding DAYBU (trofinetide) for Rett syndrome, potentially expanding its market in Europe. While this development could strengthen DAYBU's position as a second revenue pillar next to", "url": "https://www.sahmcapital.com/news/content/should-emas-positive-rett-syndrome-opinion-for-daybu-reshape-acadia-pharmaceuticals-acad-investment-narrative-2026-07-07", "source_name": "Sahm", "published_at": "2026-07-08T23:39:36", "published_display": "08 Jul 2026 23:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of ACADIA Pharmaceuticals Inc. \u2013 NASDAQ:ACAD", "summary": "This page displays the enterprise value to EBITDA forward for ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD). The data is provided by ICE Data Services and FactSet, focusing on the financial metrics for the company within the pharmaceuticals sector.", "url": "https://www.tradingview.com/symbols/NASDAQ-ACAD/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T01:11:27", "published_display": "08 Jul 2026 01:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital Adjusts Price Target on ACADIA Pharmaceuticals to $36 From $29, Maintains Outperform Rating", "summary": "RBC Capital has increased its price target for ACADIA Pharmaceuticals (ACAD) to $36 from $29, while reiterating an Outperform rating on the stock. This adjustment reflects the firm's updated valuation of the company.", "url": "https://www.moomoo.com/news/post/72582431/rbc-capital-adjusts-price-target-on-acadia-pharmaceuticals-to-36?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-07T13:09:41", "published_display": "07 Jul 2026 13:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer", "summary": "Acadia Pharmaceuticals Inc. has announced the appointment of Carl Segerstrom as Chief People Officer, effective July 6, 2026. Segerstrom will oversee the company's global people and culture strategy, supporting its expansion as a leading neurological and rare disease company. He ", "url": "https://www.biospace.com/press-releases/acadia-pharmaceuticals-appoints-carl-segerstrom-as-chief-people-officer", "source_name": "BioSpace", "published_at": "2026-07-07T11:40:33", "published_display": "07 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acadia taps 25-year HR veteran for chief people officer role", "summary": "Acadia Pharmaceuticals Inc. has appointed Carl Segerstrom as its new Chief People Officer, effective July 6. Segerstrom, who brings over 25 years of global human resources experience from the biopharmaceutical industry, will lead the company's people and culture strategy to suppo", "url": "https://www.stocktitan.net/news/ACAD/acadia-pharmaceuticals-appoints-carl-segerstrom-as-chief-people-lllmyr75lgdp.html", "source_name": "Stock Titan", "published_at": "2026-07-06T12:40:03", "published_display": "06 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of ACADIA Pharmaceuticals Inc. \u2013 LSX:603035", "summary": "The article discusses the \"Price to book forward\" metric for ACADIA Pharmaceuticals Inc. (LSX:603035). It appears to be a financial data snippet from TradingView, indicating that the market for this stock was closed with no trades recorded. The content does not provide specific f", "url": "https://www.tradingview.com/symbols/LSX-603035/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T22:40:03", "published_display": "05 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACAD - Acadia Pharmaceuticals Inc Forecast, Target Price", "summary": "This article provides comprehensive financial data for Acadia Pharmaceuticals Inc. (ACAD), including key metrics like market capitalization, P/E ratio, EPS forecasts, and sales performance. It also details insider and institutional ownership, profitability ratios, and various sto", "url": "https://finviz.com/stock?t=ACAD&ta=1&p=d&ty=fc&r=m6", "source_name": "Finviz", "published_at": "2026-07-05T22:40:03", "published_display": "05 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of ACADIA Pharmaceuticals Inc. \u2013 NASDAQ:ACAD", "summary": "This article provides access to the \"Price to sales forward\" financial metric for ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) on TradingView. It indicates that the market was closed at the time of publication and offers no trades. The content primarily focuses on navigation to fin", "url": "https://www.tradingview.com/symbols/NASDAQ-ACAD/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T13:11:46", "published_display": "05 Jul 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACAD INVESTORS WHO LOST MONEY: HAGENS BERMAN, National Trial Attorneys, Alerts Acadia Pharmaceuticals (ACAD) Investors to Securities Class Action, Advises Investors with Losses to Contact Its Attorneys Now", "summary": "Hagens Berman, a national trial law firm, is alerting investors of Acadia Pharmaceuticals (NASDAQ: ACAD) to a securities class action lawsuit. The lawsuit alleges that Acadia misrepresented facts concerning its supplemental new drug application (\"sNDA\") for NUPLAZID\u00ae (pimavanseri", "url": "https://www.newsfilecorp.com/release/83505/ACAD-INVESTORS-WHO-LOST-MONEY-HAGENS-BERMAN-National-Trial-Attorneys-Alerts-Acadia-Pharmaceuticals-ACAD-Investors-to-Securities-Class-Action-Advises-Investors-with-Losses-to-Contact-Its-Attorneys-Now?lang=fr", "source_name": "TMX Newsfile", "published_at": "2026-07-01T21:09:07", "published_display": "01 Jul 2026 21:09", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACADIA Pharmaceuticals (ACAD) In Focus As Europe Backs Daybue And Undervalued View Holds", "summary": "ACADIA Pharmaceuticals (ACAD) shares are in focus after European regulators issued a positive opinion on Daybue for Rett syndrome, causing a recent rally. Despite a 16.34% one-month return, the stock is still down 4.15% year-to-date and is considered 12.3% undervalued with a fair", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-acad/acadia-pharmaceuticals/news/acadia-pharmaceuticals-acad-in-focus-as-europe-backs-daybue", "source_name": "Simply Wall Street", "published_at": "2026-06-30T20:10:23", "published_display": "30 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Acadia Pharmaceuticals stock rating on EU progress", "summary": "H.C. Wainwright reaffirmed its Buy rating and $37 price target for Acadia Pharmaceuticals (NASDAQ:ACAD) after the CHMP issued a positive opinion for DAYBU (trofinetide) in Europe. This decision reverses a previous refusal and recommends marketing authorization for neurobehavioral", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-acadia-pharmaceuticals-stock-rating-on-eu-progress-93CH-4767555", "source_name": "Investing.com", "published_at": "2026-06-30T12:09:47", "published_display": "30 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 ACADIA Pharmaceuticals Inc For: 29 June By Investing.com", "summary": "This article announces the filing of Form 4 for ACADIA Pharmaceuticals Inc. on June 29. It includes basic information about the company and its stock performance, along with a statement from Reuters. The primary content is a headline and brief stock data.", "url": "https://ca.investing.com/news/stock-market-news/form-4-acadia-pharmaceuticals-inc-for-29-june-93CH-4712731", "source_name": "Investing.com Canada", "published_at": "2026-06-29T22:09:47", "published_display": "29 Jun 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACADIA PHARMACEUTICALS (ACAD) officer sells 11,421 shares under 10b5-1 plan", "summary": "ACADIA PHARMACEUTICALS' Principal Accounting Officer, James Kihara, sold 11,421 shares of common stock at a weighted average price of $26.0846 per share. This open-market transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 9, 2025. Follow", "url": "https://www.stocktitan.net/sec-filings/ACAD/form-4-acadia-pharmaceuticals-inc-insider-trading-activity-e01ea9f69012.html", "source_name": "Stock Titan", "published_at": "2026-06-29T21:41:28", "published_display": "29 Jun 2026 21:41", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACADIA Pharmaceuticals Price Target Raised to $35.00/Share From $32.00 by Citigroup", "summary": "Citigroup has increased its price target for ACADIA Pharmaceuticals from $32.00 to $35.00 per share. This adjustment indicates a more optimistic outlook by the firm on the company's future stock performance.", "url": "https://www.moomoo.com/news/post/72197256/acadia-pharmaceuticals-price-target-raised-to-35-00-share-from?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-29T13:41:29", "published_display": "29 Jun 2026 13:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acadia Pharmaceuticals: Steady Commercial Progress, Remlifanserin Data In Focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQSHRVYTZYd0M0LWtaOUxJRDdkVk9iVGF2RDhSQ2V3SHowdHFrNUE2MnVLd3lqWVl4bDhjSFFBT19SelpmcndyRnVheFFHN1ZhRXFRaEpQQ2VMbGVhX0ZMUFlQVTY5cGtCUFVXR3Rab2FZSXZSUTBiYWxUUzN4Q3VnOFVmSHc2MWwxTXZUdmtyUUJtSUtMSFdqTkRnVU9hM2ZDejdYSWJHQlpLeHRQQWozYnBKZUhORnM3aUE?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Strength Seen in Acadia (ACAD): Can Its 6.8% Jump Turn into More Strength?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQMUdvaE8yS3ZMb19vQlFhV2U0c0F6TGt4UnJpMmhfUVFXQ0UwQUZUUXFKSFRBWGlGdGhzbVNBTVlYMHZHVDJHR0JOSzFWendCN3lKd0RZTE5NWEpJZWtiN2lTMEFwa2paQ29KTHB1TjlXYTNjWk9UeFFkU0ItakRReFFuSUl2WWFHbnBMdHQyeGRleVJzcmxz?oc=5", "source_name": "Market source", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acadia Pharma Stock Jumps After European Panel Reverses Course On Rett Syndrome Therapy", "summary": "Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) shares are trading higher after the European Medicines Agency (CHMP) recommended granting marketing authorization for its drug DAYBU (trofinetide) to treat neurobehavioral symptoms of Rett syndrome in the EU. This follows an earlier nega", "url": "https://www.sahmcapital.com/news/content/acadia-pharma-stock-jumps-after-european-panel-reverses-course-on-rett-syndrome-therapy-2026-06-26", "source_name": "Sahm", "published_at": "2026-06-28T20:39:37", "published_display": "28 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why ACADIA Pharmaceuticals (ACAD) Is Up 17.1% After EMA Backs DAYBU For Rett Syndrome", "summary": "ACADIA Pharmaceuticals saw its stock rise by 17.1% after the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for DAYBUE (trofinetide) to treat Rett syndrome in the EU. This potential approval would make DAYBUE the first approved therapy for ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-acad/acadia-pharmaceuticals/news/why-acadia-pharmaceuticals-acad-is-up-171-after-ema-backs-da", "source_name": "Simply Wall Street", "published_at": "2026-06-28T07:39:48", "published_display": "28 Jun 2026 07:39", "sentiment": "positive", "sentiment_pct": 82, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACADIA Pharmaceuticals Up Nearly 11%, On Track for Largest Percent Increase Since May 2025 -- Data Talk", "summary": "ACADIA Pharmaceuticals (ACAD) shares increased by nearly 11% today, putting the company on track for its largest single-day percentage gain since May 2025. This significant rise highlights strong investor interest, potentially driven by recent developments or market optimism surr", "url": "https://www.moomoo.com/news/post/72119989/acadia-pharmaceuticals-up-nearly-11-on-track-for-largest-percent?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-27T07:09:58", "published_display": "27 Jun 2026 07:09", "sentiment": "positive", "sentiment_pct": 78, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] ACADIA PHARMACEUTICALS INC SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOdmlWd3FBQ1FrQTJYTGtqaF9QRkdXazhuNk5TbzNCNlZ3SDRaNENDOElvSXRGMHZQMFd6VDViX0Y5THJZazhxVHNYa3UzandGNDQ4b0ozR21QdkdpSVZ4eXJsMy1ZLW1YS2V2U3k1SExvb05ZR01EcEJmN2dveXkwcHlMTmkyQnNub3VKYkZnSnhoUmRiVUxmTHU2WkxHQmZ0Y3lTRnBn?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Acadia Pharmaceuticals Stock Is Soaring Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNTWxCUkpKUDhWSmV6RlFNakZHUjAwUTBLYk9EOFZyaUNSYzhsaE9wck1oTDRBb3hmWExaaHNoSGpSSTlXZ0J3QXJZMFNUa2l1TnJiS3VXd2lsQmVLR3BjSDl4UlAtMzFWZldwYWJlSlB1S2RUdm45NU5oVGVGMkQtVm4wbGd2UEZPdlFTaHdZQklBaFppQkh4STFxZ3RvTm4yQ0VFbnVCNXc?oc=5", "source_name": "Market source", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EU regulator backs Acadia's DAYBU for Rett syndrome", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPNFBnT2VUcDl2bUZGVTlOaUd3NlhRem9sRmh2aUFEWDYtRzdFamlTTVEtU2gxNTA5OUpXWDZMMWlTTFNrcW81d0xJWmVaUHowUzg0MllMRVV6aVFKQ1h1VS1Ma2J0N3ZuRXpWU1JqZWQzM2h2Z0dBQnhMRFZfYndkdktqUmRuYWJKeDFZMDVVVVRpWmJldGwxZTJUaEdBanBTR29fYU82cnNtWWxyZ21zOE9BSkNPMnhpSWJKdlN0Yw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACADIA Pharmaceuticals Inc. Actuals & Estimates (NASDAQ:ACAD)", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNZkhhX0xxalNLNF9waXRtNHdFaEZaV2RodUtWZXV2SUREV1FTUzM0ek41dzNnTGNsUWlZQWRzQ1dvWndlTUVkejg1cmQzd2JRZ2drTXFiTXpLdVMtWGx4eDJfd1lvZTBjakJQZVVpNzB4STlDMXVWOENiMHg1bHJOcUM1Vzk1QQ?oc=5", "source_name": "TradingView", "published_at": "2026-06-25T21:27:33+00:00", "published_display": "25 Jun 2026 21:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACADIA Pharmaceuticals: The Song Remains The Same (NASDAQ:ACAD)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNYUVvSnJZRERCZkFRVjlqYkFVX2JBNGVQSHNhbXQ4eUpTUUQtS2YwMUhmQVYzSXp3c1JBcnBjWERVLXpoUmgzT3MtS1dYMW5COXhxUFBBbGpMUmF5YnVtWTdSQjA5ai02aXNTTERiUW1NNVpITDVxaWI2QlJHWkpoRXZTLXRyc2VC?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACADIA Pharmaceuticals stock (US0042251084): earnings momentum and pipeline focus in neuroscience", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPUHpvTkZzM0pRZGdTWTRsVGNoRnZHOFd5TDcyN053bHZWeUFWdUNVRm92NlUxamZ3Ti1rVXg2YVdSMTlCbUIyS0VzV0tCM044Zjk3NmR2M0JjbXloaWl4cVpoVTl1YUFkVVhoQ3lIdlFsUGoyQU9RbTFwU3VELXpHOF9McHN4dlBVZHZGWThUYzdHbVYxZEtBV1Rkd0w3dS1NUkQzd2tEeFkzYUtjLTNxUE82UnU4Z1A5czhGZnpmSQ?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At ACADIA Pharmaceuticals (ACAD) Valuation After Recent Share Price Weakness", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOeWNzOWNoM0QteERGa2VjeHFnZ0ZLVWgyVGUyeDJRZjNqX0UtU2ZoRHRUektHMjY4cVhQYU01S3FWRnZ3Y3hkbURtNTR3ejZrcnlPRjZEUnAxY1J1SnQ0U2hLODdDUzRRVlZwZGNhM0NsTzY4X29mRlFsWlp3YWV1cGl4S3Zic1hQcGV4ZmhDQnJfWnBKSWl6VEtvYmxLejBxc00tT0JlbkVVNTQ?oc=5", "source_name": "Market source", "published_at": "2026-06-07T07:00:00+00:00", "published_display": "07 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Shareholders In ACADIA Pharmaceuticals (NASDAQ:ACAD) Should Look Beyond Earnings For The Full Story", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNMG1naUZNQXpCa2RmYVhEWGlNTFNsYXlMS2N3LUk3cnBXY0dPTElXYWV5ZTY2STBvd1dxMFBXTTlldGd6MVRuYS03Z0wzdTNwcHI0cTRkeGwxcmxFYjBOXzdfd1RqQ1lTbGRRbkVTM05lNWJQbFY3THpzbFlpb1JYNHRJcHhUdVd1Ql9yREdSd2hXQ2k3ZDc5NjNZRDZMbkJVc2RuM2VpSkRNcjFsazd1ZzBR?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is ACADIA Pharmaceuticals (ACAD) Offering Value After A 45% One Year Share Price Gain?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acadia R&D Chief Plans Retirement As Company Stresses Pipeline Continuity", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-03T07:00:00+00:00", "published_display": "03 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACADIA PHARMACEUTICALS INC ($ACAD) CEO 2025 Pay Revealed", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNMUh2aTY1QjZOZzJ4UE1mSGMxVjhEM3hBd2ZFMGRyYldGRXRpbnF4UkpyN3ptVktkVG9hNHdWbkVqdGVvMUNxNnhIZmF0VGgxVzNJMWFQNDE2S3djbUhqZ1phcW93bEZDRFdWZGdLaUZMNEpRa2RDeGg1NEgwNjF4eTJXM3c0cWRRZDNKNzQ0YmJQbVJiemxZOTNCQQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CNBC Cures: Acadia Pharmaceuticals CEO on scaling rare and neuro-focused drugs", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQcDBtTjR6dGE4LWNaRFZJaFh0MWxqV0FUNjZEWm5CYjZrUV9jN01EUzZYWVhGSUR5UUJldkFWTTZiTE8xdUNqd0habHh1TFlwWndhdlJDTTFZVG9FTmZqSXBFU1NBZjJfVWZaVXpvSDJ5QmhJOWhGV3VaaldZNktCZ2lGbGF4cG4zX3NRd0hUM0pRY183eWtlUmJvYmJpOGVJaFV5MjkwRm9yWWJ2Q1N6OVFVYnFEaXdRNVFJWg?oc=5", "source_name": "CNBC", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Revisit ACADIA Pharmaceuticals (ACAD) After Recent Share Price Weakness?", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxQemhIOTQxVGdualF2NHdkNk5TRGxwQ1p6a0l0V2NEaDFJczZmRzAxZnRTRGx2NDhoR1JTNmc5X1F2eHNDclAwV2ZnT2NfZXBUWUZtSkpQOUtBal9acW5BUVRsZHFhZXk1WG56anlkODJSRUQ2cmZNbVcya0lYdlQ0UFJtekEyendobzV6TzI1WQ?oc=5", "source_name": "Market source", "published_at": "2026-03-04T08:00:00+00:00", "published_display": "04 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will ACADIA Pharmaceuticals' (ACAD) 2025 Earnings Beat and 2026 Guidance Shift Its Growth Narrative?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxOMlNJdm53WXJkaE1PVXJGYmhBbnBCOU13cE52djB4VDZDazhzTFFrMndIdVhsZEliVjMyREh5dHhWN21NRVNKdmtRN3lsT0Flb3J0NWhHVmhFeEJvR1hPeHM5bWtzSHZySE9vMV8wQ3pYZzdlNVNqME5yVnFzcmhuRXdINEdKX1ZaYVVjdXhtTmw?oc=5", "source_name": "Market source", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACADIA Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-09T08:00:00+00:00", "published_display": "09 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acadia Pharmaceuticals (ACAD) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1YMlYxeXZrMkFqbmpBb3VrWlJZb1ZmYjdDYXBfZmd3blFwMGpxYnhJRnBWUFdfbkRpRVkydV9lWjdWbW5NVllMNFdKVjNKSmVVeXBV?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T01:14:47+00:00", "published_display": "25 Apr 2025 01:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxQSW9mM3I5d1lnaHgzVDlPNFgzSVg3MFNNVmk0N0hLcGh3dko0MF9kWUVzS1phTmdDU1NjUGFZamZZWTBmdnFfanllME9NWmhxd0JiMjJzM3JCQU9SVnY0cEx3T3JnT1pDUlh3Vy0xR1lDem9hZ2ZqdUFXd2UzU1JRbkczUEdHZ1hSRGdTN1JfSHgtLUxQVTBJRjNGbS15Z05pZVd0a25wZl9OX0VjNnp4WHVVOUxxeUVwbTJ1TmdMTzZvcEZVbTkzSDdEUFhvZTdtZC1fb3R2SFZ4ZzQ?oc=5", "source_name": "StockStory", "published_at": "2026-07-15T07:00:00+00:00", "published_display": "15 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 95, "total_relevant": 55, "sentiment_summary": {"positive": 19, "negative": 3, "neutral": 33, "score": 57, "total": 55, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 80, "events": [{"event": "general", "label": "Market update", "weight": 17.0, "count": 29}, {"event": "earnings", "label": "Earnings", "weight": 9.21, "count": 19}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.65, "count": 3}], "positive_events": 19, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 26.22, "latest_week": "2026-07-10", "one_week_move": 1.0, "four_week_move": 24.3, "twelve_week_move": 18.3, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.955929, "market_dynamics_buy_signal": false, "relative_strength": -4.899611, "fair_value_gap": 23.4, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "negative", "expectation_probability": 39.8005, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+1.0% over one week, +24.3% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 66, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 14}, {"label": "Stock Titan", "count": 6}, {"label": "TradingView", "count": 5}, {"label": "simplywall.st", "count": 5}, {"label": "Moomoo", "count": 4}, {"label": "Sahm", "count": 3}, {"label": "Simply Wall Street", "count": 3}, {"label": "BioSpace", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 46}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 29}, {"label": "Earnings", "count": 19}, {"label": "Analyst action", "count": 4}, {"label": "Regulatory and legal", "count": 3}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "80/100 classification confidence."}, {"label": "Company focus", "value": "46", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+1.0% over one week, +24.3% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026"}], "updated_at": "2026-07-16T17:01:12.567960+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}